The announcement of an oversubscribed and upsized underwritten offering of common stock and concurrent private placement typically leads to a dilution of existing shares, which can result in a decrease in share price. Given that this news directly pertains to Biodesix and its financial actions, it is highly relevant and important for investors, leading to a negative short-term impact on the stock price.